(732): Patients’ experience with fentanyl effervescent buccal tablets: Interim analysis of a long-term, multicenter, open-label study in cancer-related breakthrough pain

Abstract

Fentanyl effervescent buccal tablets (FEBT) are designed to enhance the rate and efficiency of fentanyl absorption through the buccal mucosa. The results reported here represent the 3-month interim analysis of an ongoing safety study of FEBT in the treatment of cancer-related breakthrough pain (BTP). The study enrolled patients who were receiving stable doses of around-the-clock opioids for baseline pain and supplemental opioids for BTP. As of July 29, 2005, 129 participants (aged 24 to 95 years) constituted the safety population of the open-label phase, having consumed at least 1 dose of FEBT (100-800 μg).